New data shows subcutaneous LEQEMBI matches IV efficacy for early Alzheimer's, offering easier dosing.

Eisai and Biogen presented data at AAIC 2026 showing that LEQEMBI's subcutaneous autoinjector delivers similar efficacy and safety to intravenous administration for early Alzheimer's disease. The once-weekly 500 mg subcutaneous dose achieves comparable drug exposure to the IV regimen, potentially allowing more convenient at-home treatment if FDA approved. Real-world data also indicate slower cognitive decline and high patient satisfaction with the subcutaneous form, supporting its use for long-term disease management.